Critical Contrast: Silverback Therapeutics (NASDAQ:SBTX) vs. UCB (OTCMKTS:UCBJF)

UCB (OTCMKTS:UCBJF) and Silverback Therapeutics (NASDAQ:SBTX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.

Profitability

This table compares UCB and Silverback Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
UCB	N/A	N/A	N/A
Silverback Therapeutics	N/A	-29.62%	-28.20%

Earnings & Valuation

This table compares UCB and Silverback Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
UCB	$5.27 billion	9.66	$371.23 million	N/A	N/A
Silverback Therapeutics	N/A	N/A	-$89.48 million	($2.42)	-4.70

UCB has higher revenue and earnings than Silverback Therapeutics.

Volatility and Risk

UCB has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, Silverback Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for UCB and Silverback Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
UCB	0	0	2	0	3.00
Silverback Therapeutics	0	0	0	0	0.00

Insider and Institutional Ownership

74.9% of Silverback Therapeutics shares are held by institutional investors. 34.4% of Silverback Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

UCB beats Silverback Therapeutics on 6 of the 9 factors compared between the two stocks.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

About Silverback Therapeutics

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.